Boston Scientific and Amos Gazit Ltd Announce New Distribution Partnership Agreement in Israel

PARIS, April 8, 2014 /PRNewswire/ --



Boston Scientific BV has signed a distribution partnership agreement with Amos Gazit Ltd in Israel. Under the new partnership, Amos Gazit Ltd will market and distribute Boston Scientific's Interventional Cardiology - excluding the Watchman™ Left Atrial Appendage Occlusion device -, Peripheral Interventions, Endoscopy and Urology/Women's Health products.

"We are delighted to start this new partnership in Israel with Gazit Limited which will help us ensure physicians and patients have optimal access to Boston Scientific's best in class technology," said Mauro Trucco, vice president Emerging Markets, Boston Scientific. "The decision has been made in partnership with Medison and Gazit Ltd."

"We are very excited to enter theses medical fields with one of the world's leading technology companies. We believe that this will be a long-term and successful partnership that, combined with our existing business, will create a significant growth synergy for Gazit and Boston Scientific," said Oded Gazit, Joint Managing Director at Amos Gazit Ltd.

Mr. Meir Jakobsohn, Medison's Founder and CEO, added that: "Medison has made this decision as part of a strategic policy to focus on our core fields, such as innovative niche pharmaceuticals and technologies. We thank Boston Scientific for their trust and support through the years and wish both companies success in their new partnership."

The partnership agreement has started on April 7, 2014.

About Boston Scientific 

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit http://www.bostonscientific.com and connect on Twitter and Facebook.

About Gazit 

Amos Gazit Ltd is a leading Israeli company, family owned and dealing in import, marketing, exporting and service for a wide variety of products in the field of safety and medicine for the institutional, business and private sectors. Amos Gazit Ltd was established in 1958, and during all its years of activity has strived to promote the subjects of health and safety in Israel. Amos Gazit Ltd, in conjunction with leading manufacturers world-wide, constantly updates and introduces to the Israeli market the latest improvements and technologies, while maintaining the highest level of quality and integrity. The company employs more than 100 employees at the Petach Tikva headquarters. The company comprises 3 divisions : safety division, medical division and technical support division, all working together to promote the values defined at the founding of the company : protecting the health and safety of each individual in Israel.

About Medison 

Medison is Israel's leading marketing group, representing innovative niche healthcare solutions companies such as Biogen Idec., Amgen, Shire and Ipsen. Employing a comprehensive approach to sales and service, Medison supplies and maintains long-standing relations with HMOs (Health Maintenance Organizations), local medical centers and physicians. Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli, Romanian and Slovakian healthcare markets. Medison has offices and is active in Israel and Romania.

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches, regulatory approvals, clinical and product performance and importance, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.